Form 4: Exelixis Director Sue Gail Eckhardt Receives RSU Grant

Director Sue Gail Eckhardt was granted 8,367 restricted stock units by Exelixis, Inc. on May 27, 2026.

Summary

• Director Sue Gail Eckhardt acquired 8,367 restricted stock units (RSUs) of Exelixis, Inc. common stock.
• The grant was issued under the Exelixis, Inc. 2017 Equity Incentive Plan.
• The RSUs are scheduled to vest 100% on May 27, 2027, contingent upon continuous service.
• Following this transaction, the reporting person's total beneficial ownership is 25,891 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the reporting person's continuous service through the vesting date.

Future Outlook

The RSUs will vest in full on May 27, 2027, provided the director remains in continuous service with the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with shareholder interests.

Comparison to Industry Standards

• The use of 2017 Equity Incentive Plans for director compensation is consistent with standard practices for mid-to-large cap biotechnology firms.
• The one-year cliff vesting schedule for director RSUs is a common retention mechanism in the industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 8,367 RSUs on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation